KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Cash & Equivalents (2016 - 2026)

Pacira BioSciences has reported Cash & Equivalents over the past 17 years, most recently at $144.3 million for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 49.12% year-over-year to $144.3 million; the TTM value through Mar 2026 reached $144.3 million, down 49.12%, while the annual FY2025 figure was $158.5 million, 42.72% down from the prior year.
  • Cash & Equivalents for Q1 2026 was $144.3 million at Pacira BioSciences, down from $158.5 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $300.5 million in Q2 2025 and troughed at $35.5 million in Q1 2023.
  • A 5-year average of $172.1 million and a median of $153.3 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: crashed 84.32% in 2023 and later skyrocketed 417.8% in 2024.
  • Year by year, Cash & Equivalents stood at $104.1 million in 2022, then surged by 47.21% to $153.3 million in 2023, then soared by 80.55% to $276.8 million in 2024, then plummeted by 42.72% to $158.5 million in 2025, then fell by 8.98% to $144.3 million in 2026.
  • Business Quant data shows Cash & Equivalents for PCRX at $144.3 million in Q1 2026, $158.5 million in Q4 2025, and $147.6 million in Q3 2025.